Both in Biotechnology
Halozyme Therapeutics vs Repligen
Over the past year HALO returned +94.3% and RGEN returned +18.7%; their daily moves had a correlation of 0.22.
HALO +94.3% RGEN +18.7%Growth of $1, one year, split-adjusted
| Metric | HALO | RGEN |
|---|---|---|
| Price | $128.62 | $178.27 |
| Market cap | $14.60B | $11.32B |
| Today | −0.26% | +3.08% |
| 1 month | +18.8% | −5.9% |
| 6 months | +95.3% | +41.9% |
| Year to date | +91.1% | +8.8% |
| 1 year | +97.3% | +19.6% |
| Revenue growth (YoY) | +47.7% | +10.9% |
| Gross margin | 83.5% | 53.0% |
| Net margin | 47.8% | −18.4% |
| P/E (TTM) | 35.3× | — |
| Price / sales | 8.8× | 14.0× |
| Net cash | -$1.92B | $307.4M |
| Dividend yield | — | — |
| Volatility (60d) | 27.8% | 47.3% |
| Short % of float | 12.4% | 12.8% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).